Compare Bristol-Myers Squibb Co (BMY) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Standard Lithium Ltd — how do they compare? Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B), while Standard Lithium Ltd trades at $2.41 (market cap $604.50M). The key difference: Bristol-Myers Squibb Co is far larger — about 215× Standard Lithium Ltd's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| BMY | SLI | |
|---|---|---|
Market Cap | $129.94B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $5.65 |
52-Week Low | $42.60 | $1.93 |
Enterprise Value | $163.92B | $467.42M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SLI trades at $2.43, down 3.95% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported negative profitability metrics, including a -16.6% ROE and -$48.40M net income for 2025, but has beaten EPS estimates in two recent quarters. Recent news highlights institutional buying and progress on its South West Arkansas lithium project, supported by a $225M DOE grant.
The outlook hinges on successful project execution and lithium production timeline, with analyst consensus strongly bullish (100% buy ratings). Key risks include persistent negative cash flow from operations and high capital expenditure needs, which could pressure the balance sheet if project delays occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
